MCH (human, mouse, rat)
Cat. No. 3806
Alternative Name: Melanin-concentrating hormone (human, mouse, rat)
Biological ActivityPotent endogenous agonist at melanin-concentration hormone (MCH) receptors (IC50 values are 0.3 and 1.5 nM and EC50 values are 3.9 and 0.1 nM at MCH1 and MCH2 receptors respectively). Increases food intake in vivo.
(Modifications: Disulfide bridge between 7-16)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Sailer et al (2001) Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc.Natl.Acad.Sci.USA 98 7564.
If you know of a relevant reference for MCH (human, mouse, rat) please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses MCH (human, mouse, rat) from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: MCH (human, mouse, rat), supplier, potent, endogenous, MCH, agonists, receptors, melanin-concentration, hormone, MCH1, MCH2, MCH2R, MCHR2, MCH1R, MCHR1, Melanin-concentrating, Melanin, concentrating, concentration, Tocris Bioscience, Melanin-concentrating Hormone Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Negative control for ELA-32 (Cat.No.6291).ELA-32 (human)
Potent, high affinity apelin receptor agonist; stimulates angiogenesisParathyroid hormone (1-34) (bovine)
Parathyroid hormone (PTH) receptor agonist.Parathyroid hormone (1-34) (rat)
Parathyroid hormone (PTH) receptor agonistPeptide YY (3-36) human
NPY Y2 receptor agonistELA-14 negative control
Negative control for ELA-14 (Cat.No.6293).ELA-14 (human)
Potent apelin (APJ) receptor agonistRetrobradykinin
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailable
August 20 - 24, 2017
Paris , France